Napatt Kanjanahattakij
Interventional Cardiology · Reno, NVNPI 1871943183
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,314 of the $9,561 with a category attached, or 87.0%. 24 manufacturers reported payments, led by Abbott at 34.1% of the total. Reporting peaked in 2023 at $2,531 and has fallen 61.8% since, to $967 in 2025. That places this record below the midpoint for interventional cardiology clinicians in NV, where the typical reported total is $9,708.
Across 312 payments — averaging $30.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Edwards Lifesciences$2K
- Boston Scientific$1K
- Shockwave Medical, Inc$617
- Abiomed$484
- E.r. Squibb & Sons, L.L.C.$458
- plus $2K from 18 others
What the payments were for
- Travel & lodging$1,03311%
- Food & beverage$8,31487%
- Education$2142%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 205 | $3,265 |
| Edwards Lifesciences | 11 | $1,642 |
| Boston Scientific | 21 | $1,160 |
| Shockwave Medical, Inc | 5 | $617 |
| Abiomed | 8 | $484 |
| E.r. Squibb & Sons, L.L.C. | 11 | $458 |
| Biotronik Inc. | 11 | $315 |
| Novartis | 7 | $194 |
| Impulse Dynamics (USA) Inc. | 2 | $174 |
| Philips North America LLC | 4 | $153 |
| Boehringer Ingelheim | 6 | $145 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $145 |
| AstraZeneca | 2 | $137 |
| Medtronic | 2 | $129 |
| Alnylam Pharmaceuticals Inc. | 2 | $116 |
| Cordis US CORP. | 1 | $102 |
| Cathworks, Inc. | 1 | $84 |
| Penumbra, Inc. | 1 | $63 |
| Lexicon Pharmaceuticals, Inc. | 2 | $45 |
| Novo Nordisk | 1 | $33 |
| Merck | 2 | $29 |
| Siemens Medical Solutions USA, Inc. | 2 | $28 |
| Amgen | 1 | $27 |
| Lantheus Medical Imaging, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$568
- Edwards SAPIEN 3 Transcatheter Heart Valve$426
- OPTIMIZER$286
- WATCHMAN Access System$225
- CAMZYOS$214
- Impella$208
- Ensite Cardiac Mapping System$151
- DRAGONFLY OPSTAR$150
- MitraClip$144
- General - Balloon Catheters$144
- CROSSBOSS$142
- AMPLATZER AMULET$137
- WATCHMAN FLX$135
- SAPIEN 3 Ultra RESILIA$135
- LEQVIO$131
- FARXIGA$125
- ELIQUIS$118
- MYNX CONTROL$102
How this compares
$9,561 in reported general payments places this provider in the 45th percentile of 62 interventional cardiology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 152 | $201,599 |
| JardianceEmpagliflozin | 44 | $66,118 |
| XareltoRivaroxaban | 46 | $56,225 |
| EntrestoSacubitril/Valsartan | 18 | $31,695 |
| BrilintaTicagrelor | 21 | $14,791 |
| Repatha SureclickEvolocumab | 25 | $14,486 |
| FarxigaDapagliflozin Propanediol | 16 | $13,111 |
| Atorvastatin Calcium | 266 | $3,110 |
| Ezetimibe | 63 | $2,297 |
| Metoprolol Succinate | 190 | $2,138 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 16 | $2,048 |
| ClopidogrelClopidogrel Bisulfate | 71 | $1,841 |
| Amiodarone Hcl | 33 | $1,747 |
| Losartan Potassium | 168 | $1,245 |
| Potassium Chloride | 31 | $987 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $145 | $66,11844 claims |
| NovartisEntresto | $194 | $31,69518 claims |
| AstraZenecaBrilinta, Farxiga | $137 | $27,90237 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 62 interventional cardiology providers in Nevada.
Other interventional cardiology in Reno
- Lina Ya'qoubReno$30K
- Abhilash AkinapelliReno$14K
- Bradley NelsonReno$13K
- Jad Al DanafReno$10K
- Benjamin EbnerReno$10K
- Troy WiedenbeckReno$5K
- Hideki IchinoReno$5K
- Chanwit RoongsritongReno$3K
- Robert SwackhamerReno$797
- Michael NewmarkReno$323
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.